Nothing found for ""

Sorry, but nothing matches your search terms
Please try again with some different keywords

A study by Dalhousie University on behalf of the Dutch medical cannabis producer Bedrocan adds another challenge to the long-debated designation of cannabis strains as indica, sativa, and hybrid.

Well-known cannabinoid researcher Ethan Russo presented the study at the 9th IACM cannabinoid congress in Cologne, Germany Sept. 29, 2017. The recent study is the third scientific work since 2013 that finds there is no scientific basis for the widely used modern classification of cannabis strains.

Researchers analyzed the genetic makeup of 149 Dutch cannabis samples and found a lack of genetic distinction between indica and sativa samples. In plant taxonomy, specific rules dictate which family, genus, and species are used to categorize a plant. These categorizations help scientists and growers identify plants with similar characteristics and provide an avenue for predicting the traits they'll carry, such as smell, appearance, and therapeutic properties.

When it comes to cannabis, however, the lack of available resources for research over the past few decades has resulted in a deeply-rooted folk taxonomy that oversimplifies the complex makeup of cannabis and disregards what scientists are finding to be the key indicator of a cannabis cultivar's effects — terpenes.

This study shows that the indica-sativa differences could be largely based on terpene content, which instead of the current indica/sativa labeling might require more insight into the terpene profiles ... Click To Tweet

“This study shows that the indica-sativa differences could be largely based on terpene content, which instead of the current indica/sativa labeling might require more insight into the terpene profiles related to the Bedrocan products available for patient use,” Hugo Maassen, head of the phyto engineering department at Bedrocan, stated in a press release.

Russo is not the first researcher to doubt the naming system adopted by what was once exclusively a black market. As early as 2013, the owner of a test laboratory for medical cannabis who has a Ph.D. in chemistry from the University of Southern California in Los Angeles was questioning the significance of the indica-sativa designation of strains purchased in California.

Jeffrey Raber and his staff collected and tested more than 1,000 different samples for a total of 42 compounds. The founder of the Werc Shop was sure the classifications had been faulty. Dr. Raber and his team not only found there was no scientific basis for the different effects associated with sativa or indica, but he also proved that what's being sold as OG Kush in one shop could be something completely different in another.

“Most people don't even know,” Raber said in an interview with LA Weekly. “We took a popular name, Jack Herer, and found that most didn't even look like each other. OG whatever, Kush whatever, and the marketing that goes along with it — it's not really medically designed.”

Two Strains, Similar Genetics

Researchers from the University of British Columbia and Dalhousie University tested medical cannabis from Canada in 2015 to search for similarities in the origin and active ingredient profiles of different strains declared as indica or sativa. The Canadian scientists were looking for the origins of different fiber hemp varieties as well as some THC-rich cannabis varieties. Besides the fiber hemp samples, they compared 83 THC-rich strains sourced from licensed Canadian producers and could not find a uniform pattern in either sativa or indica varieties.

A Jamaican Lamb's Bread strain was presented as 100 percent sativa origin, but was genetically almost identical to a pure indica from Afghanistan, confirming Raber's 2013 conclusion that common strain names have little scientific or medicinal value.

“Cannabis breeders and growers often indicate the percentage of sativa or indica in a cannabis strain, but they are not very accurate,” explained the study's author Jonathan Page in a press release. “Right now, the genetic identity of a marijuana strain cannot be accurately determined by its name or reported ancestry. Ultimately we require a practical, accurate and more reliable classification system of this plant.”

Authorities Missed the Train

Authorities around the world have missed many opportunities to address the cannabis classification issue. Prohibitions have made it nearly impossible to create a consistent, unified system for identifying cultivars. Instead, they go by meaningless names in the U.S. and the Netherlands, or a cryptic number, as is the case in Canada.

Despite the vast acceptance of medical marijuana in the United States, the federal government classifies cannabis under the Controlled Substances Act as Schedule I, meaning a drug with no medicinal value, which restricts the country's scientists and researchers from classifying plants in a way that's more beneficial and clear for medical patients.

When the Netherlands passed its medical cannabis program in spring 2014, the Office for Medical Cannabis (OMC) refused to accept any varieties that were already known in coffeeshops and purchased there as herbs. As a result, the breeders with the world's largest repositories, who had developed many varieties that since the mid-1980s have spawned today's gene pool, were excluded right from the start.

Marijuana prohibitions have made it nearly impossible to create a consistent, unified system for identifying cultivars.

Health Canada gave manufacturers the opportunity to obtain strains from patients with an expiring cultivation license during a 2014 transitional period that initially took cultivation out of the hands of patients who were growing their own medicine, and placed it under the purview of producers who lacked adequate seed banks. While pragmatic and compassionate in the short term, it did nothing to address the issue of scientific classification for medical uses.

Recreational users have been making do with Indica, Sativa and Hybrid classifications for decades. Just like wine lovers, cannasseurs do not need their passion to be classified scientifically.

When it comes to medical cannabis, however, practicing physicians such as Dr. Bonni Goldstein would prefer that all products are labeled with cannabinoid potency and terpenoid profiles.

“Medical patients and recreational users alike know what works when they use cannabis but often the information of the makeup of that chemovar may be unknown. Knowing what works allows for reproducible results,” Goldstein told Marijuana.com.

Because consumers have become used to this folk taxonomy in cannabis, a major overhaul will become all the more difficult. Probably almost as difficult as the introduction of the metric system in the United States.